Do digital biomarkers represent an opportunity to effectively capture primary endpoints in a clinical trial? Are digital biomarkers capable of reducing variability when measuring subjective primary endpoints (e.g in neurological diseases such as Parkinson or Alzheimer)? How do we select and develop digital biomarkers that are solid enough to prove the efficacy of a drug in a clinical trial? What digital measures are already in use in clinical research and what have we learned so far? How should digital biomarkers be standardized so that regulatory agencies accept them as valid data?